<DOC>
	<DOCNO>NCT02072434</DOCNO>
	<brief_summary>The purpose study compare edoxaban ( investigational drug ) warfarin enoxaparin , see safe effective prevent stroke blood clot complication subject atrial fibrillation whose doctor plan treat electrical cardioversion . It expect 284 site recruit 2200 subject North America , EU , Russia , Ukraine Israel . Participants randomly allocate receive either treatment edoxaban , treatment warfarin , plus enoxaparin require . Participants equal chance receive either treatment . Participants study maximum 82 day . Study procedure include physical examination , vital sign ( pulse sit blood pressure ) , ECG ( electrocardiogram ) , finger prick blood clotting test , blood sample , urine sample completion Quality Life questionnaire . The study expect show edoxaban provide comparable incidence rate efficacy warfarin plus enoxaparin , current standard treatment , least safe warfarin incidence rate bleeding</brief_summary>
	<brief_title>Edoxaban vs. Warfarin Subjects Undergoing Cardioversion Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Signed informed consent Male female old minimum legal adult age ( country specific ) Ongoing AF last least 48 hrs &lt; = 12 month Subject Planned Electrical Cardioversion .AF transient reversible No rhythm issue AF Mitral stenosis rheumatic disease , unresected atrial myxoma mechanical heart valve Left atrial appendage closure thrombus MI , stroke , ACS , PCI within 30 day High risk bleed within 10 day randomization Dual antiplatelet therapy List prohibit concomitant medication Active liver disease Renal failure , CrCl &lt; 15 ml/min Hemoglobin &lt; 10g/dl platelet count &lt; 100000 cells/microliter Taking investigational drug Women childbearing potential proper contraceptive measure Active cancer require chemotherapy/radiation/surgery Investigator discretion base examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>anti-coagulant</keyword>
	<keyword>warfarin</keyword>
	<keyword>edoxaban</keyword>
	<keyword>electrical cardioversion</keyword>
</DOC>